NEW BRUNSWICK, N.J. / Apr 22, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29th, at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm (Eastern Time).
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
The audio webcast replay will be available approximately 48-hrs after the webcast.
| Last Trade: | US$158.97 |
| Daily Change: | 5.06 3.29 |
| Daily Volume: | 5,657,818 |
| Market Cap: | US$383.110B |
April 15, 2025 April 02, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
